This document is a published patent application from the USPTO detailing a novel intranasal pharmaceutical composition for the acute treatment of migraine and other forms of headache. The composition combines ibuprofen and ketoprofen at a fraction of the dose typically required for oral administration, aiming for enhanced efficacy and potentially reduced side effects. The application also covers the manufacturing method for preparations containing this combination.

While patent applications do not impose direct regulatory obligations on companies, they signal potential future market exclusivity for specific drug formulations and delivery methods. Companies involved in migraine treatment or drug delivery systems should monitor this application and related patents, as it may impact their own research, development, and commercialization strategies. The filing date was September 24, 2024, with publication anticipated on March 26, 2026.